Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBITDA: 2009-2021

Historic EBITDA for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to -$85.5 million.

  • Avadel Pharmaceuticals' EBITDA fell 62.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$85.5 million, marking a year-over-year decrease of 1571.13%. This contributed to the annual value of -$85.5 million for FY2021, which is 1571.13% down from last year.
  • According to the latest figures from FY2021, Avadel Pharmaceuticals' EBITDA is -$85.5 million, which was down 1,571.13% from $5.8 million recorded in FY2020.
  • Avadel Pharmaceuticals' 5-year EBITDA high stood at $89.5 million for FY2017, and its period low was -$104.9 million during FY2018.
  • Over the past 3 years, Avadel Pharmaceuticals' median EBITDA value was -$24.1 million (recorded in 2019), while the average stood at -$34.6 million.
  • In the last 5 years, Avadel Pharmaceuticals' EBITDA soared by 1,902.72% in 2017 and then slumped by 1,571.13% in 2021.
  • Avadel Pharmaceuticals' EBITDA (Yearly) stood at $89.5 million in 2017, then plummeted by 217.23% to -$104.9 million in 2018, then soared by 77.02% to -$24.1 million in 2019, then surged by 124.12% to $5.8 million in 2020, then slumped by 1,571.13% to -$85.5 million in 2021.